Literature DB >> 14632744

Polarity of helper T cell subsets represents disease nature and clinical course of experimental autoimmune myocarditis in rats.

K Fuse1, M Kodama, M Ito, Y Okura, K Kato, H Hanawa, S Aoki, Y Aizawa.   

Abstract

The mechanisms of progression, remission and relapse of myocarditis remain unclear. To clarify these mechanisms, we focused on T helper-1 (Th1)/T helper-2 (Th2) subsets balance of peripheral lymphocytes and serum cytokine levels during disease progression in rats with experimental autoimmune myocarditis (EAM). Lewis rats were immunized with cardiac myosin on day 0. Blood samples were collected on days 0, 7, 15, 18, 21, 28, 35, 42, 49 and 56 following immunization. We examined percentages of interferon (IFN)-gamma and/or interleukin (IL)-4 producing cells in stimulated peripheral CD4-positive lymphocytes using flow cytometry analysis. Serum IFN-gamma, IL-2, IL-6 and IL-10 levels were measured by enzyme-linked immunosorbent assay (ELISA). The percentage of Th1/Th2 subsets in EAM on days 0, 15, 28 and 56 were 2.5 +/- 0.5/0.5 +/- 0.1%, 19.4 +/- 3.2/1.6 +/- 0.3%, 2.0 +/- 0.5/22.1 +/- 5.7% and 3.0 +/- 0.4/1.7 +/- 0.3%, respectively. Serum levels of Th1 cytokines, IFN-gamma and IL-2 significantly increased in the acute phase (from day 15-18) and immediately decreased in the early recovery phase. On the other hand, serum levels of Th2 cytokine, IL-10 significantly increased in the early recovery phase (from day 24-30). These results suggest that induction of acute myocarditis might be associated with systemic Th1 dominance, while recovery is related to systemic Th2 polarity. Thus, analysis of Th1/Th2 balance in peripheral T cells may be useful in disease monitoring in patients with myocarditis and postmyocarditic dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14632744      PMCID: PMC1808899          DOI: 10.1111/j.1365-2249.2003.02312.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

Review 1.  Cytokines that regulate autoimmune responses.

Authors:  M Falcone; N Sarvetnick
Journal:  Curr Opin Immunol       Date:  1999-12       Impact factor: 7.486

2.  Time course of gene expression in rat experimental autoimmune myocarditis.

Authors:  Haruo Hanawa; Satoru Abe; Manabu Hayashi; Tsuyoshi Yoshida; Kaori Yoshida; Takaaki Shiono; Koichi Fuse; Masahiro Ito; Hitoshi Tachikawa; Takeshi Kashimura; Yuji Okura; Kiminori Kato; Makoto Kodama; Seitaro Maruyama; Tadashi Yamamoto; Yoshifusa Aizawa
Journal:  Clin Sci (Lond)       Date:  2002-12       Impact factor: 6.124

3.  Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype.

Authors:  M Afanasyeva; Y Wang; Z Kaya; S Park; M J Zilliox; B H Schofield; S L Hill; N R Rose
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Experimental autoimmune myocarditis and its pathomechanism.

Authors:  T Izumi; H Takehana; C Matsuda; H Yokoyama; K Kohno; K Suzuki; T Inomata
Journal:  Herz       Date:  2000-05       Impact factor: 1.443

5.  Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway.

Authors:  M Afanasyeva; Y Wang; Z Kaya; E A Stafford; K M Dohmen; A A Sadighi Akha; N R Rose
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

6.  Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction.

Authors:  U Eriksson; M O Kurrer; R Bingisser; H P Eugster; P Saremaslani; F Follath; S Marsch; U Widmer
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

7.  Suppression of myocardial inflammation using suramin, a growth factor blocker.

Authors:  Takaaki Shiono; Makoto Kodama; Haruo Hanawa; Koichi Fuse; Tadashi Yamamoto; Yoshifusa Aizawa
Journal:  Circ J       Date:  2002-04       Impact factor: 2.993

8.  Protection against autoimmune myocarditis by gene transfer of interleukin-10 by electroporation.

Authors:  K Watanabe; M Nakazawa; K Fuse; H Hanawa; M Kodama; Y Aizawa; T Ohnuki; F Gejyo; H Maruyama; J Miyazaki
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

9.  Dual role of the IL-12/IFN-gamma axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-gamma.

Authors:  U Eriksson; M O Kurrer; W Sebald; F Brombacher; M Kopf
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

10.  Th1/Th2 balance alteration in the clinical course of a patient with acute viral myocarditis.

Authors:  K Fuse; M Kodama; Y Aizawa; M Yamaura; Y Tanabe; K Takahashi; K Sakai; T Miida; H Oda; N Higuma
Journal:  Jpn Circ J       Date:  2001-12
View more
  11 in total

1.  A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy.

Authors:  Fadia Ali Kamal; Kenichi Watanabe; Meilei Ma; Yuichi Abe; Reyad Elbarbary; Makoto Kodama; Yoshifusa Aizawa
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Effect of hydrodynamics-based delivery of IL-18BP fusion gene on rat experimental autoimmune myocarditis.

Authors:  He Chang; Yan Wang; Gang Li; Le Zhang; Guang Wei Zhang; Yan Chun Liao; Haruo Hanawa; Jun Zou
Journal:  Clin Exp Med       Date:  2014-11       Impact factor: 3.984

3.  Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.

Authors:  Shyam S Bansal; Mohamed Ameen Ismahil; Mehak Goel; Bindiya Patel; Tariq Hamid; Gregg Rokosh; Sumanth D Prabhu
Journal:  Circ Heart Fail       Date:  2017-03       Impact factor: 8.790

4.  CD4+/CD25+ T-Lymphocytes and Th1/Th2 regulation in dilated cardiomyopathy.

Authors:  I Efthimiadis; P Skendros; A Sarantopoulos; P Boura
Journal:  Hippokratia       Date:  2011-10       Impact factor: 0.471

5.  Recombinant cardiac myosin fragment induces experimental autoimmune myocarditis via activation of Th1 and Th17 immunity.

Authors:  Melvin D Daniels; Kenneth V Hyland; Kegiang Wang; David M Engman
Journal:  Autoimmunity       Date:  2008-09       Impact factor: 2.815

6.  Analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in anti-CD4 monoclonal antibody treated mice with autoimmune cardiomyopathy.

Authors:  Zhaohui Wang; Yuhua Liao; Jing Yuan; Jinghui Zhang; Jihua Dong; Jinping Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

Review 7.  Advances in monoclonal antibody application in myocarditis.

Authors:  Li-na Han; Shuang He; Yu-tang Wang; Li-ming Yang; Si-yu Liu; Ting Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2013-08       Impact factor: 3.066

8.  Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.

Authors:  Vijayakumar Sukumaran; Punniyakoti T Veeraveedu; Narasimman Gurusamy; Ken'ichi Yamaguchi; Arun Prasath Lakshmanan; Meilei Ma; Kenji Suzuki; Makoto Kodama; Kenichi Watanabe
Journal:  Int J Biol Sci       Date:  2011-09-08       Impact factor: 6.580

9.  Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis.

Authors:  Vijayakumar Sukumaran; Kenichi Watanabe; Punniyakoti T Veeraveedu; Narasimman Gurusamy; Meilei Ma; Rajarajan A Thandavarayan; Arun Prasath Lakshmanan; Ken'ichi Yamaguchi; Kenji Suzuki; Makoto Kodama
Journal:  Int J Biol Sci       Date:  2011-02-11       Impact factor: 6.580

10.  Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats.

Authors:  Keiji Okuda; Hai Ying Fu; Takashi Matsuzaki; Ryo Araki; Shota Tsuchida; Punniyakoti V Thanikachalam; Tatsuya Fukuta; Tomohiro Asai; Masaki Yamato; Shoji Sanada; Hiroshi Asanuma; Yoshihiro Asano; Masanori Asakura; Haruo Hanawa; Hiroyuki Hao; Naoto Oku; Seiji Takashima; Masafumi Kitakaze; Yasushi Sakata; Tetsuo Minamino
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.